Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of lebrikizumab in idiopathic pulmonary fibrosis
2013-001163-24Phase 2Completed
- Sponsor
- Roche
- Start
- Aug 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lebrikizumab in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Roche. Primary endpoint: Annualized rate of decrease in percent predicted FVC over 52 weeks. Started Aug 2013; status: completed.
02
Drugs
lebrikizumab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2013-001163-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001163-24.